ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > prospectus details on use of funds raised recently

<< Previous

Bullboard Posts

Next >>

Comment by farmerjaneon Dec 07, 2020 10:23am

103 Views

Post# 32048887

RE:RE:prospectus details on use of funds raised recently

I believe as a condition ot the Prospectus they had to file for the special warrants, they needed to show where they intend to spend the dollars. Not sure why they went the special warrant course. Most importantly what's become of there research over the course of the year and prior years? PMN310 (2018), PD, ALS, Sereology test (Elliot ipod by end of 3rd quarter), AD testing announced this year in feb a 6 month trilal with Toronto Memory? No news nothing?

<< Previous

Bullboard Posts

Next >>

Bombardier delivers Global 6500 aircraft to U.S. Army